Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer
Source: genomeweb, August 2021
Nouscom said on Tuesday it has dosed the first patient in a Phase Ib trial of its neoantigen cancer vaccine, NOUS-PEV, plus pembrolizumab (Merck’s Keytruda) in patients with advanced melanoma and non-small cell lung cancer.
The trial is evaluating the combination as a first-line treatment in up to 34 patients with unresectable stage III or IV cutaneous melanoma and PD-L1-positive stage IV NSCLC.
